Potential strategies include: 1) developing anti‐ANGPTL8 monoclonal antibodies or PIRB blockers to intercept the liver‐kidney axis; 2) repurposing 5‐LOX/FLAP inhibitors (e.g., zileuton) for macrophage‐specific inflammatory treatment of CKD; and 3) using serum ANGPTL8 as a novel biomarker for risk stratification of CKD progression in NAFLD patients. Here, ALOX5AP is linked to metabolic dysfunction-associated steatotic liver disease.